Edition:
United States

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

1.45USD
15 Dec 2017
Change (% chg)

$-0.02 (-1.36%)
Prev Close
$1.47
Open
$1.50
Day's High
$1.50
Day's Low
$1.45
Volume
30,008
Avg. Vol
60,509
52-wk High
$6.98
52-wk Low
$0.50

Chart for

About

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition,... (more)

Overall

Beta: 1.84
Market Cap(Mil.): $29.19
Shares Outstanding(Mil.): 20.13
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Pulmatrix posts Q3 net loss of $0.22 per share

* Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials

Nov 09 2017

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

Sep 06 2017

BRIEF-Pulmatrix says generated no revenue in Q2 of 2017

* Pulmatrix provides 2017 company year-to-date highlights and q2 2017 updated financials

Aug 04 2017

Earnings vs. Estimates